{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:39Z","timestamp":1761870519942,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.clml.2013.03.005","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T20:53:42Z","timestamp":1371156822000},"page":"398-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Multicenter, Open-Label, Noncomparative Screening Study of Enzastaurin in Adult Patients With Non-Hodgkin Lymphomas"],"prefix":"10.1016","volume":"13","author":[{"given":"Cecily J.","family":"Forsyth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gomez-Almaguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnny F.C.","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"Eliadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erick","family":"Crespo-Solis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar H.","family":"Gutierrez-Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Rivas-Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Roberson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil V.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oday","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.03.005_bib1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1002\/cncr.20245","article-title":"Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma","volume":"100","author":"Rizzieri","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.03.005_bib2","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.005_bib3","unstructured":"Delmer A. Current treatment of T-cell lymphomas: are we making any progress? Hematology Education: the Education Program for the Annual Congress of the EHA 2007; 1:83-88. Available at: http:\/\/online.haematologica.org\/supplements\/Hematology_Education_2007.pdf. Accessed: May 6,\u00a02013."},{"key":"10.1016\/j.clml.2013.03.005_bib4","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","article-title":"Evaluation of the Revised European-American Lymphoma Classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma","volume":"89","author":"Melnyk","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.005_bib5","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d\u2019Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.005_bib6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.1989.7.12.1783","article-title":"Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma","volume":"7","author":"Armitage","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.005_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives)","volume":"1","author":"Coiffier","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2013.03.005_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ajcp\/83.3.279","article-title":"Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes","volume":"83","author":"Grogan","year":"1985","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2013.03.005_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's Lymphoma Classification Project","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2013.03.005_bib10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2006-03-012021","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII","volume":"109","author":"Abrams","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.005_bib11","first-page":"261","article-title":"Effects of XW630 on cell proliferation, iNOS activity, and cGMP content in human osteoblast-like cell line TE85","volume":"21","author":"Sun","year":"2000","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clml.2013.03.005_bib12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4049\/jimmunol.167.2.636","article-title":"Cutting edge: protein kinase C beta expression is critical for export of Il-2 from T cells","volume":"167","author":"Long","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2013.03.005_bib13","first-page":"233","article-title":"Modulation of CD40L antigen expression in Jurkat cells: involvement of protein kinase C activity","volume":"41","author":"Lisowska","year":"2003","journal-title":"Folia Histochem Cytobiol"},{"key":"10.1016\/j.clml.2013.03.005_bib14","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.4049\/jimmunol.163.11.5813","article-title":"Protein kinase ctheta cooperates with calcineurin to induce Fas ligand expression during activation-induced T cell death","volume":"163","author":"Villalba","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2013.03.005_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0925-4439(02)00163-1","article-title":"Differential expression of protein kinase C isoenzymes related to high nitric oxide synthase activity in a T lymphoma cell line","volume":"1588","author":"Gorelik","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2013.03.005_bib16","doi-asserted-by":"crossref","first-page":"18081","DOI":"10.1073\/pnas.0506216102","article-title":"MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation","volume":"102","author":"Felli","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2013.03.005_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0268-960X(03)00004-3","article-title":"Primary cutaneous lymphomas: a review with current treatment options","volume":"17","author":"Querfeld","year":"2003","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2013.03.005_bib18","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","article-title":"The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","volume":"65","author":"Graff","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.03.005_bib19","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.005_bib20","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.005_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.138.1.42","article-title":"Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT)","volume":"138","author":"Stevens","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2013.03.005_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.005_bib23","unstructured":"National Cancer Institute. 2006. Cancer therapy evaluation program Common Terminology Criteria for Adverse Events, version 3.0. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed: March 11,\u00a02011."},{"issue":"suppl","key":"10.1016\/j.clml.2013.03.005_bib24","article-title":"Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies","volume":"28","author":"Furman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.005_bib25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1158\/1078-0432.CCR-09-1837","article-title":"Clinical and translational studies of a phase ii trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed\/refractory Waldenstr\u00f6m's macroglobulinemia","volume":"16","author":"Ghobrial","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.03.005_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.121.121","article-title":"A\u00a0phase II trial of the oral mTOR inhibitor Everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL)","volume":"110","author":"Reeder","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.005_bib27","doi-asserted-by":"crossref","unstructured":"Schwartzberg L, Hermann RC, Flinn IW, et\u00a0al. Enzastaurin in patients with follicular lymphoma: results of a phase II study. J Clin Oncol ASCO Annual Meeting Proceedings 2010; 28(suppl):8040.","DOI":"10.1200\/jco.2010.28.15_suppl.8040"},{"key":"10.1016\/j.clml.2013.03.005_bib28","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1158\/1078-0432.CCR-12-0181","article-title":"A\u00a0multicenter phase II study of single-agent enzastaurin in previously treated Waldenstr\u00f6m macroglobulinemia","volume":"18","author":"Ghobrial","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:48Z","timestamp":1761870228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S2152265013000992"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.03.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Multicenter, Open-Label, Noncomparative Screening Study of Enzastaurin in Adult Patients With Non-Hodgkin Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}